Research article

The CYP2J2 G-50T polymorphism and myocardial infarction in patients with cardiovascular risk profile

Jan Börgel^1* , Daniel Bulut^1* , Christoph Hanefeld¹ , Horst Neubauer¹ , Andreas Mügge¹ , Jörg T Epplen² , Tim Holland-Letz³ and Martin Spiecker⁴

¹  Department of Cardiology, St. Josef Hospital/Bergmannsheil, Ruhr-University, Bochum, Germany

²  Department of Human Genetics, Ruhr-University, Bochum, Germany

³  Department of Medical Informatics, Biometry and Epidemiology, Ruhr-University, Bochum, Germany

⁴  Department of Cardiology, Marienhospital, Marl, Germany

author email corresponding author email* Contributed equally

BMC Cardiovascular Disorders 2008, 8:41doi:10.1186/1471-2261-8-41

Published:	23 December 2008

Abstract

Background

Cytochrome P450 (CYP) enzyme 2J2, an epoxygenase predominantly expressed in the heart, metabolises arachidonic acid to biologically active eicosanoids. One of the CYP2J2 products, 11, 12-epoxyeicosatrienoic acid, has several vasoprotective effects. The CYP2J2-G-50T-promotor polymorphism decreases gene expression and is associated with coronary artery disease. This association supports the vascular protective role of CYP-derived eicosanoids in cardiovascular disease. In the present study, we investigated the influence of this polymorphism on survived myocardial infarction in two study groups of patients with on average high cardiovascular risk profile.

Methods

The CYP2J2 polymorphism was genotyped in two groups of patients that were collected with the same method of clinical data collection. Data from 512 patients with sleep apnoea (group: OSA) and on average high cardiovascular risk profile and from another 488 patients who were admitted for coronary angiography (CAR-group) were evaluated for a potential correlation of the CYP2J2 polymorphism G-50T and a history of myocardial infarction. The G-50T polymorphism of the CYP2J2 gene was genotyped by allele specific restriction and light cycler analysis.

Results

The T-allele of the polymorphism was found in 111 (11.1%; CAR-group: N = 65, 13.3%; OSA: N = 46, 9.0%). 146 patients had a history of myocardial infarction (CAR: N = 120, 24.6%; OSA: N = 26, 5.1%). Cardiovascular risk factors were equally distributed between the different genotypes of the CYP2J2 G-50T polymorphism. In the total group of 1000 individuals, carriers of the T-allele had significantly more myocardial infarctions compared to carriers of the wild type (T/T or G/T: 21.6%; G/G: 13.7%; p = 0.026, odds ratio 1.73, 95%-CI [1.06–2.83]). In the multivariate logistic regression analysis the odds ratio for a history of myocardial infarction in carriers of the T-allele was 1.611, 95%-CI [0.957–2.731] but this trend was not significant (p = 0.073).

Conclusion

In presence of other risk factors, the CYP2J2 G-50T failed to show a significant role in the development of myocardial infarction. However, since our result is close to the border of significance, this question should be clarified in larger, prospective studies in the future.